【券商聚焦】东北证券维持微创脑科学(02172)“买入”评级指核心产品海外放量

金吾资讯09-06

金吾财讯 | 东北证券发研报指，微创脑科学(02172)发布2024年上半年业绩公告，2024H1公司实现营业收入4.08亿元(+36.44%)，归母净利润1.44亿元(+124.08%)，业绩高速增长，费用率下降明显，盈利能力大幅提升。该行表示，公司研发成果丰硕，缺血类与通路类产品线进一步完善。2024年H1共有5款产品顺利获批上市，包括Neuro Guard神经血管球囊导引导管、...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2465689915?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-09-06 08:56","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2465689915","market":"hk","top_or_hot":-1,"title":"【券商聚焦】东北证券维持微创脑科学(02172)“买入”评级 指核心产品海外放量","media":"金吾资讯","content":"<div>\n<p>金吾财讯 | 东北证券发研报指，微创脑科学(02172)发布2024年上半年业绩公告，2024H1公司实现营业收入4.08亿元(+36.44%)，归母净利润1.44亿元(+124.08%)，业绩高速增长，费用率下降明显，盈利能力大幅提升。该行表示，公司研发成果丰硕，缺血类与通路类产品线进一步完善。2024年H1共有5款产品顺利获批上市，包括Neuro Guard神经血管球囊导引导管、...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024090608571995e5dd9b&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>【券商聚焦】东北证券维持微创脑科学(02172)“买入”评级 指核心产品海外放量</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n【券商聚焦】东北证券维持微创脑科学(02172)“买入”评级 指核心产品海外放量\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-06 08:56 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024090608571995e5dd9b&s=b><strong>金吾资讯</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>金吾财讯 | 东北证券发研报指，微创脑科学(02172)发布2024年上半年业绩公告，2024H1公司实现营业收入4.08亿元(+36.44%)，归母净利润1.44亿元(+124.08%)，业绩高速增长，费用率下降明显，盈利能力大幅提升。该行表示，公司研发成果丰硕，缺血类与通路类产品线进一步完善。2024年H1共有5款产品顺利获批上市，包括Neuro Guard神经血管球囊导引导管、...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024090608571995e5dd9b&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02172","symbol_name":"微创脑科学","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024090608571995e5dd9b&s=b","article_id":"2465689915","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024090608571995e5dd9b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2465689915","pubTimestamp":1725584217,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"目前公司累计在中国获批上市产品共21款，在研产品共14款，其中4款产品获纳入绿色通道。有望持续补充公司产品序列，贡献业绩增量。该行考虑到公司是中国神经介入医疗器械行业的龙头企业，市场份额长年稳居国产品牌第一，多款创新产品预计放量。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["rate"],"viewcount":null,"language":"zh","relate_stocks":{"02172":"微创脑科学"},"translate_title":"[Brokerage Focus] Northeast Securities maintains the \"buy\" rating of Minimally Invasive Brain Science (02172), referring to the overseas volume of core products","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02172":1},"content_text":"金吾财讯 | 东北证券发研报指，微创脑科学(02172)发布2024年上半年业绩公告，2024H1公司实现营业收入4.08亿元(+36.44%)，归母净利润1.44亿元(+124.08%)，业绩高速增长，费用率下降明显，盈利能力大幅提升。该行表示，公司研发成果丰硕，缺血类与通路类产品线进一步完善。2024年H1共有5款产品顺利获批上市，包括Neuro Guard神经血管球囊导引导管、Neurohawk取栓支架2代、Safecer栓塞保护器及Path Finder颈动脉球囊扩张导管、Tubridge Plus密网支架顺利获批。目前公司累计在中国获批上市产品共21款，在研产品共14款，其中4款产品获纳入绿色通道。有望持续补充公司产品序列，贡献业绩增量。该行续指，公司2024H1年海外收入为2812万元(+87%)，产品销售收入在APAC、EMEA及LATAM、EMEA地区分别实现123%、14%、120%及85%的增长。公司共计8款产品成功开拓国际市场，公司产品累计在韩国、美国、巴西等21个海外国家实现商业化，覆盖神经介入手术量排名全球前十国家中的9个，其中美国销售于一季度由经销转直销。该行考虑到公司是中国神经介入医疗器械行业的龙头企业，市场份额长年稳居国产品牌第一，多款创新产品预计放量。公司专注自主支持产权研发和创新，拥有涵盖脑卒中三大脑血管疾病领域的全面商业化产品组合与多项全球或全国首款产品，竞争优势突出。预期公司2024-2026年营业收入为9.23/12.08/15.11亿元；归母净利润为2.87/3.95/5.06亿元。EPS分别为0.49/0.68/0.87元；对应PE分别为15.04/10.92/8.53倍，高增长低估值，维持公司“买入”评级。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.28.3","shortVersion":"4.28.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2465689915"}

【券商聚焦】东北证券维持微创脑科学(02172)“买入”评级 指核心产品海外放量

精彩评论

【券商聚焦】东北证券维持微创脑科学(02172)“买入”评级指核心产品海外放量